Researchers have genetically changed a herpes virus to target an antibody for “destroying tumors and to generate an anti-tumor immune response,”
The Herpes virus is one of akind that causes cold sores.
Gray Frame Corner
The cold-virus-treatment termed RP2, is in phase 1 clinical trials, with 36 people enrolled, and the preliminary outcomes are promising.
Medium Brush Stroke
The findings were shown at a medical conference in Paris, according to the BBC news.
Overall, the data represented that tumors shrank in three out of nine people given RP2.
Seven out of 30 patient who had a mixed treatment also seemed to benefit.
There were mild side effects like tiredness.
It is very rare to observe such decent responses at the early stages of trials.
Similar technology from this was approved in the UK to treat cancer.
In order to get allowance for RP2 to treat solid tumors, there will require to be more clinical trials with a huge group of people.
Cream Section Separator